Intermittent clobazam therapy and febrile seizure recurrence – A follow up study


Original Article

Author Details : Cyril Ignatious Rozario, Sunil Daniel*, Anzy N Saleem

Volume : 7, Issue : 1, Year : 2021

Article Page : 24-27

https://doi.org/10.18231/j.ijmpo.2021.006



Suggest article by email

Abstract

Objectives: To identify the proportion of children on intermittent clobazam therapy developing febrile seizure recurrence and to assess the risk factors of febrile seizure recurrence in children. 
Design: Descriptive follow up study.
Study setting: Children between 6 months to 5 years admitted in Govt.TDMCH for seizures associated with fever.
Materials and Methods: Children presenting with acute febrile seizures are started on intermittent clobazam therapy. The risk factors were assessed and study group is followed up for a period of one year. Data were analyzed using computer software SPSS. Data are expressed in its frequency and percentage as well as mean and standard deviation. To elucidate the associations and comparisons between different parameters, Chi square(X2) test was used as non-parametric test.
Results: Out of the 80 children followed up 28 children developed recurrence. Those who took clobazam had considerable reduction in recurrence (8.3% in clobazam group compared to 56.8% in those who were not on intermittent clobazam therapy. Complex febrile seizures (Odds ratio of 16.5 and p value <.01) and history of febrile seizures in the first degree relatives (Odds ratio of 3.81 and p value of <.01) had increased chance of recurrence.
Conclusion: Intermittent clobazam therapy has definite role in preventing febrile seizure recurrence. The risk factors for considering intermittent prophylaxis from this study are family history of febrile seizure and complex febrile seizure.

Keywords: Febrile seizure, Recurrence, Clobazam.

 


How to cite : Rozario C I, Daniel S , Saleem A N, Intermittent clobazam therapy and febrile seizure recurrence – A follow up study. IP Int J Med Paediatr Oncol 2021;7(1):24-27


Copyright © 2021 by author(s) and IP Int J Med Paediatr Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)



View Article

PDF File   Full Text Article


Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijmpo.2021.006


Article Metrics






Article Access statistics

Viewed: 106

PDF Downloaded: 41